Kidney International · 2019 · 52 citations · 12 references
MedicineImmunologyPathologyAutoimmunityImmunopathologyInflammationComplement-mediated InjuryGlomerular InjuryImmune-mediated InjuryRenal ImmunopathologyRenal InflammationTubulointerstitial DiseasesComplement ComponentsComplement In Disease PathogenesisComplement-mediated DamageComplement-mediated GlomerulonephritisComplement-mediated GlomerulopathyComplement-mediated InflammationMembrane Attack ComplexTubulointerstitial Damage Biomarkers
Complement plays an important role in the pathogenesis of lupus nephritis (LN). With the emergence of therapeutic complement inhibition, there is a need to identify patients in whom complement-driven inflammation is a major cause of kidney injury in LN. Clinical and histopathological data were obtained retrospectively from 57 biopsies with class III, IV, and V LN. Biopsies were stained for complement components C9, C5b-9, C3c, and C3d and for the macrophage marker CD68. C9 and C5b-9 staining were highly correlated (r = 0.92 in the capillary wall). C5b-9 staining was detected in the mesangium and/or capillary wall of both active and chronic proliferative LN in all but one biopsy and in the capillary wall of class V LN in all biopsies. C5b-9 staining intensity in the tubular basement membrane correlated with markers of tubulointerstitial damage, and more intense capillary wall C5b-9 staining was significantly associated with nonresponse to conventional treatment. Glomerular C5b-9 staining intensity did not differ between active and chronic disease; in contrast, C3c and CD68 staining were associated with active disease. Evaluation of serial biopsies and comparison of staining in active and chronic LN demonstrated that C5b-9 staining persisted for months to years. These results suggest that C5b-9 staining is almost always present in LN, resolves slowly, and is not a reliable marker of ongoing glomerular C5 activation. This limits the utility of C5b-9 staining to identify patients who are most likely to benefit from C5 inhibition.
12
Yijun Wang, Qiongzheng Hu, Joseph A. Madri et al. · Proceedings of the National Academy of Sciences · 1996 · 341 citations · Full text
Medicine, Immunology, Pathology +17
Ronald J. Falk, Agustin P. Dalmasso, Y Kim et al. · Journal of Clinical Investigation · 1983 · 201 citations · Full text
Medicine, Immunology, Pathology +17
Pathology after Eculizumab in Dense Deposit Disease and C3 GN
Leal Herlitz, Andrew S. Bomback, Glen S. Markowitz et al. · Journal of the American Society of Nephrology · 2012 · 153 citations · Full text
Medicine, Nephrology, Pathology +17
Sjoerd A.M.E.G. Timmermans, Myrurgia A. Abdul‐Hamid, Judith Potjewijd et al. · Journal of the American Society of Nephrology · 2018 · 96 citations · Full text
Medicine, Nephrology, Pathology +17